Literature DB >> 9153551

Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee.

A C Bakker1, L A Joosten, O J Arntz, M M Helsen, A M Bendele, F A van de Loo, W B van den Berg.   

Abstract

OBJECTIVE: To determine the efficacy of local human interleukin-1 receptor antagonist (HuIL-1Ra) gene therapy in murine collagen-induced arthritis (CIA).
METHODS: DBA/1 mice were immunized against bovine type II collagen. Before the onset of arthritis, NIH/3T3 fibroblasts transfected with pMFG-IRAP were transplanted into the knee cavity. Normal NIH/3T3 cells served as controls. Paws were evaluated macroscopically for redness, swelling, and deformities during the course of arthritis. Swelling of the knee joints was measured by external gamma counting of 99mtechnetium accumulation in the joint. Paws and knee joints were dissected and processed for histologic studies to evaluate inflammation and cartilage destruction.
RESULTS: The NIH/3T3 fibroblasts survived in the joint cavity of DBA mice for at least 7 days. The transduced cells expressed immunoreactive and bioactive HuIL-1Ra in the knee joint, and produced sufficient amounts to block the effect of 1 ng of recombinant murine IL-1alpha on chondrocyte proteoglycan synthesis. The onset of CIA was almost completely prevented in knee joints containing HuIL-1Ra-producing cells, whereas joints containing normal cells showed severe inflammation and destruction of cartilage. Moreover, onset of CIA in the draining joints (ipsilateral paws) of the HuIL-1Ra gene-bearing knees was also prevented.
CONCLUSION: Local production of HuIL-1Ra in the knee was able to ameliorate the effects of IL-1 on cartilage and could prevent the onset of CIA not only in that knee, but also in the "draining" paw. This indicates the feasibility of gene transfer as a therapeutic approach to modulating arthritis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153551     DOI: 10.1002/art.1780400517

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  41 in total

Review 1.  Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.

Authors:  B Bresnihan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

4.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 5.  Gene therapy for rheumatoid arthritis.

Authors:  P D Robbins; C H Evans; Y Chernajovsky
Journal:  Springer Semin Immunopathol       Date:  1998

6.  A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis.

Authors:  Onno J Arntz; Jeroen Geurts; Sharon Veenbergen; Miranda B Bennink; Ben T van den Brand; Shahla Abdollahi-Roodsaz; Wim B van den Berg; Fons A van de Loo
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

Review 7.  Perspectives on the use of gene therapy for chronic joint diseases.

Authors:  Steven C Ghivizzani; Elvire Gouze; Jean-Noel Gouze; Jesse D Kay; Marsha L Bush; Rachael S Watson; Padraic P Levings; David M Nickerson; Patrick T Colahan; Paul D Robbins; Christopher H Evans
Journal:  Curr Gene Ther       Date:  2008-08       Impact factor: 4.391

8.  Computational design and application of endogenous promoters for transcriptionally targeted gene therapy for rheumatoid arthritis.

Authors:  Jeroen Geurts; Leo A B Joosten; Nozomi Takahashi; Onno J Arntz; Anton Glück; Miranda B Bennink; Wim B van den Berg; Fons A J van de Loo
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

Review 9.  Treatment of rheumatoid arthritis with IL-1 inhibitors.

Authors:  C Gabay; W P Arend
Journal:  Springer Semin Immunopathol       Date:  1998

Review 10.  Joint inflammation and cartilage destruction may occur uncoupled.

Authors:  W B van den Berg
Journal:  Springer Semin Immunopathol       Date:  1998
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.